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Patients with multiple myeloma (MM) who relapse after autologous transplantation have limited therapeutic
options. We conducted a prospective, multicenter, phase IIa study to investigate the safety and efﬁcacy of i.v.
busulfan (Bu) in combination with bortezomib as a conditioning regimen for a second autotransplantation.
Because a safeBuexposurewasunknown inpatients receiving this combination, Buwas initially targeted to a total
areaunder theconcentrationetimecurve (AUC) of 20,000mMminute. Asnoconcentration-limiting toxicitywas
observed in 6 patients, this Bu exposurewas utilized in the following treatment cohort (n¼ 24). Individualized Bu
dose, based on test dose .8 mg/kg pharmacokinetics (PK), was administered daily for 4 consecutive days starting
5 days before transplantation, followed by a single dose of bortezomib (1.3 mg/m2) 1 day before transplantation.
The total mean dose of i.v. Bu (including the test dose and 4-day administration) was 14.2 mg/kg (standard
deviation ¼ 2.48; range, 8.7 to 19.2). Conﬁrmatory PK demonstrated that only 2 of 30 patients who underwent
transplantationwere dosed outside the Bu AUC target and dose adjustments weremade for the last 2 doses of i.v.
Bu. The median age was 59 years (range, 48 to 73). Median time from ﬁrst to second transplantation was
28.0 months (range, 12 to 119). Of 26 evaluable patients, 10 patients attained a partial response (PR) or better at
3months after transplantation,with 2patients attaininga complete response.At 6months after transplantation, 5
of 12 evaluable patients had maintained or improved their disease status. Median progression-free survival was
191 days, whereas median overall survival was not reached during the study period. The most common grade 3
and 4 toxicities were febrile neutropenia (50.0%) and stomatitis (43.3%). One transplantation-related death was
observed.A combinationof dose-targeted i.v. Bu andbortezomib induced PRorbetter inone third of patientswith
MMwho underwent a second autotransplantation, with acceptable toxicity.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.dgments on page 1956.
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There are limited therapeutic options for patients with
autotransplantation as salvage therapy. The ﬁrst autotransplantation had to
be performed at least 1 year before the second autotransplantation.multiple myeloma (MM) who relapse after autologous blood
progenitor cell transplantation. Immune modulators and
proteosome inhibitors are frequently used after auto-
transplantation, but patients eventually relapse or develop
toxicities that preclude therapy with these agents. A second
autotransplantation can induce durable remissions in
selected patients with MM [1-7].
The addition of oral busulfan (Bu) to melphalan as a
conditioning regimen for autotransplantation resulted in
better disease control of MM compared with melphalan
monotherapy [8,9]. Unfortunately, sinusoidal obstructive
syndrome (SOS), a frequent complication of oral Bu, hindered
its use as part of the conditioning regimen [10]. Because Bu
improves the response to melphalan, we elected to investi-
gate the safety and efﬁcacy of a higher dose of i.v. Bu in pa-
tients who relapsed after autologous transplantation, as
these patients are at least partially resistant to melphalan.
Intravenous Bu eliminates the unpredictable bioavailability
of the oral formulation, which results in decreased incidence
of SOS [11,12]. However, differences in Bu metabolism can
cause suboptimal tumor exposure in approximately one
third of patients when i.v. Bu dose is calculated by body
weight [13]. Recent studies have demonstrated that the
optimal Bu exposure is correlated with good clinical out-
comes in other hematologic malignancies [14]. When doses
are adjusted based on pharmacokinetic (PK) results, inter-
individual variability of the Bu metabolism can be taken
into account, resulting in optimal therapeutic exposure [15-
18]. Thus, therapeutic dose monitoring is useful for safety
and efﬁcacy.
Preclinical and clinical studies suggest that bortezomib
potentiates the cytotoxicity of alkylating agents and other
chemotherapy agents [19,20]. Bortezomib has been added to
high-dose melphalan as part of the conditioning regimen for
multiple myeloma [21,22]. This combination is safe and
effective in patients with MM and correlative studies suggest
that bortezomib administered after the melphalan induces
more apoptosis of myeloma cells that when administered
before the melphalan [21]. The combination of Bu and bor-
tezomib has not been investigated. Here, we report the re-
sults from a prospective multicenter phase IIa study to
examine the safety and efﬁcacy of dose-targeted i.v. Bu in
combination with bortezomib as a novel conditioning
regimen for a second autotransplantation in patients with
MM who relapsed after a previous autotransplantation. We
also wanted to ascertain if PK analysis after a test dose of i.v.
Bu could be used to determine the individual dose that is
necessary to reach the target total area under the concen-
trationetime curve (AUC) of Bu used in this conditioning
regimen.
MATERIALS AND METHODS
Study Design
This was a phase IIa, single-arm, open-label, exploratory study. The
primary objective was to evaluate the safety and efﬁcacy of the novel
combination of i.v. Bu and bortezomib. The study consisted of 2 segments:
selection of the target Bu exposure, and the safety and efﬁcacy component. A
secondary objective was to examine whether PK analysis after a test dose of
i.v. Bu allowed for accurate dose targeting of Bu as part of the conditioning
regimen.
Study Eligibility
Patients ages 18 to 75 years with an Eastern Cooperative Oncology
Group performance status of 0 to 2 were enrolled. All patients had relapsed
MM after a ﬁrst autotransplantation and were eligible for a secondIt was required that patients had adequate pretransplantation organ
function, deﬁned as left ventricular ejection fraction  45% without un-
controlled arrhythmias or symptomatic cardiac disease; forced expiratory
volume in 1 second, forced vital capacity, and carbon monoxide diffusion
capacity of at least 50% of predicted; liver transaminases 3 times the upper
limit of normal; and serum creatinine < 2 mg/dL. Patients must have a
minimum peripheral blood stem cell dose of 2.0  106 CD34þ cells/kg.
Patients who had t(4;14) or p53 gene deletion at any time during the
disease were ineligible, as were patients with systemic amyloidosis [23]. We
also excluded patients who previously underwent allogeneic trans-
plantation and those with a history of having a total serum bilirubin >2 mg/
dL after chemotherapy or at study screening. Patients with grade 1 neu-
ropathy with pain or> grade 2 neuropathywithout painwere also excluded.
All patients providedwritten informed consent to participate in this study in
accordance with the Declaration of Helsinki ethical principles. The trial was
registered at www.clinicaltrials.gov as NCT01009840.
Determination of Target Total AUC
Because a safe Bu exposure was unknown in patients receiving this
combination, Bu exposure was initially targeted to an AUC of 20,000 mM 
minute, as this dose was well tolerated in people with other hematologic
malignancies [24,25]. Six to 12 patients were to be enrolled in a 3-patient
cohort schedule to determine the safety of the Bu exposure. If
concentration-limiting toxicity (CLT)ddeﬁned as treatment-related mor-
tality (TRM) or SOSdoccurred, it was planned to de-escalate the target AUC
to 16,000 mM minute. If no CLT occurred during a period of observation of
30 days, 3 additional patients were to be treated at the same target. If no
CLT were observed in the second cohort, the target dose of 20,000 mM 
minute were to be used in the next study segment to determine the safety
and efﬁcacy of this combination in 24 additional patients. No dose escalation
above 20,000 mM  minute was planned as it is known that SOS risk is
higher when the total Bu AUC exceeds 24,000 mM  minute [26-28].
Test Dose, PK Analysis, and Dose Recommendations
A test dose, .8 mg/kg, of i.v. Bu based on actual body weight (BW) or
adjusted ideal BW (AIBW) was administered over 2 hours once between
days 12 to 9 (Figure 1). The dosing algorithm for the test dose was as
follows: ﬁrst, the ideal BW (IBW) was calculated using the formulas: IBW
(kg) ¼ 50 þ .91 (height in cme152) for men; IBW (kg) ¼ 45 þ .91 (height
in cme152) for women. The actual BW was used when the actual BW was
less than or equal to the IBW; the AIBW was used when the actual BW was
greater than the IBW. The AIBW was calculated as the IBW plus 25% of the
difference between the actual BW and the IBW.
Six serial blood samples were drawn as follows: at the end of infusion
(EOI), immediately after a 2-hour infusion, EOI þ 15 minutes,
EOI þ 30 minutes, and 240, 300, and 360 minutes after the start of the
infusion of i.v. Bu. The Seattle Cancer Care Alliance measured Bu concen-
trations, determined Bu exposure as AUC using WinNonlin software version
5.2 (Pharsight Corporation, Mountain View, CA), and recommended indi-
vidualized PK-directed dosing for the conditioning regimen [29,30]. Target
daily AUC during the conditioning regimenwas calculated as: (20,000 mM 
minuteetest PK AUC)/4. The individualized daily dose for the conditioning
regimen was calculated as: (test PK dose/test PK AUC)  target daily AUC.
The individualized daily dose was calculated to achieve 20,000 mMminute
as a total AUC, including the AUC exposure from the test PK.
Conditioning Regimen and Conﬁrmatory PK Analysis
Individually dosed i.v. Bu was administered over 3 hours once daily from
day 5 through day 2. Conﬁrmatory PK was performed on day 5
(Figure 2). Samples were collected immediately at EOI, EOI þ 15 minutes,
EOI þ 30 minutes, and 270, 360, and 480 minutes after start of infusion. If
conﬁrmatory PK analysis demonstrated that the Bu exposure would be
outside the target range (20,000 mM  minute  20%, or 16,000 to
24,000 mMminute), the dose of i.v. Bu on days3 and2was adjusted. On
day1, bortezomib 1.3 mg/m2 was administered as a 3 to 5-second bolus i.v.
injection. Seizure prophylaxis with lorazepam and/or levetiracetam started
1 day before the initiation of Bu and continued until the day after the last Bu
dose [31].
Concomitant Medications
Concomitant medications were accounted for during the study period.
The following drugs known to have drug interactions with busulfan were
prohibited 72 hours before i.v. Bu treatment through 48 hours after treat-
ment: acetaminophen, voriconazole, metronidazole, digoxin, other alkylat-
ing agents, vaccines, herbal supplements, ﬁlgrastim, or sargramostin. The
following medications were discouraged during the trial: nonsteroidal anti-
Figure 1. Preconditioning test pharmacokinetics (PK) (ﬁrst PK) and conditioning regimen. A test dose, .8 mg/kg, of i.v. busulfan (Bu) based on actual body weight
(BW) or adjusted ideal BW was administered over 2 hours between days 12 and 9. Plasma samples were used to calculate Bu concentrations at the laboratory of
Seattle Cancer Care Alliance. Bu exposure was measured as area under the curve (AUC) using WinNonlin software and the individualized daily dose for the con-
ditioning regimen was calculated as: (test PK dose/test PK AUC)  target daily AUC, to achieve 20,000 mM  minute as a total AUC, including the AUC exposure from
the test PK. The individualized dose of i.v. Bu was administered over 3 hours once daily from day 5 through day 2. The second PK (conﬁrmatory PK) was performed
on day 5. Only when conﬁrmatory PK analysis indicated that Bu exposure would be outside the target range were doses on days 3 and 2 adjusted. Bortezomib
(1.3 mg/m2 once daily) was administered as a 3 to 5-second bolus i.v. injection on day 1.
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thioguanine, or immunosuppressive agents.
Maintenance Therapy After Second Transplantation
There was no restriction for maintenance therapy after the second
autotransplantation because its standard use had not been established at the
time of the study.Figure 2. Pharmacokinetics (PK) sampling times for preconditioning test PK (ﬁrst PK
drawn at the end of infusion (EOI) after a 2-hour infusion of i.v. Bu, EOI þ 15 minu
intravenous (i.v.) Bu. For the conﬁrmatory PK, plasma samples were collected at the E
and 8 hours after start of the infusion of i.v. Bu.Safety Assessment
The Common Terminology Criteria for Adverse Events version 3 was
utilized to deﬁne adverse events (AEs). A 12-lead electrocardiogram (ECG)
was obtained on screening and 3 consecutive ECGs were obtained on day1
to rule out QT prolongation. A data safety monitoring board, chaired by an
external transplantation physician, reviewed the safety data at the end of
the AUC selection and after one half of the study subjects were enrolled.) and conﬁrmatory PK (second PK). For test PK, 6 serial blood samples were
tes, EOI þ 30 minutes, and 4, 5, and 6 hours after the start of the infusion of
OI after a 3-hour infusion of i.v. Bu, EOI þ 15 minutes, EOI þ 30 minutes, 4.5, 6,
Table 1
Subject Demographics
Variable Value
Age, median (range), yr 59 (48-73)
Gender
Male 25 (83.3)
Female 5 (16.7)
Race
Caucasian 26 (86.7)
African American 4 (13.3)
ECOG performance status
Grade 0 11 (36.6)
Grade 1 18 (60.0)
Grade 2 1 (3.3)
Body weight, median (range), kg 89.9 (51.5-131.6)
Body mass index, median (range), kg/m2 31.2 (18.9-41.0)
Body surface area, median (range), m2 2.08 (1.52-2.58)
Ig subtype*
IgG 18 (60.0)
IgA 4 (13.3)
Light chain 9 (30.0)
Cytogenetic abnormality at initial diagnosis
Yes 11 (36.7)
No 17 (56.7)
Unknown/not evaluable 2 (6.7)
Residual neuropathy without pain at enrollment
Grade 1 18 (60.0)
Grade 2 2 (6.7)
Prior chemotherapy history
Bortezomib 26 (86.7)
Thalidomide 14 (46.7)
Lenalidomide 20 (66.7)
Salvage or reinduction therapy for relapsed
myeloma before the second
autotransplantation
Bortezomib-based regimens 11 (36.7)
Lenalidomide-based regimens 5 (16.7)
Lenalidomide, bortezomib, and dexamethasone 4 (13.3)
Dexamethasone, thalidomide, cisplatin,
doxorubicin, cyclophosphamide, and
etoposide
2 (6.7)
Bendamustine-based regimen 1 (3.3)
Time from ﬁrst to second transplantation,
median (range), mo
28.0 (12-119)
Time from initial diagnosis to second
transplantation, median (range), mo
38.5 (19-125)
Disease response at second autotransplantation
VGPR 7 (23.3)
PR 12 (40.0)
SD 2 (6.7)
PD 9 (30.0)
ECOG indicates Eastern Cooperative Oncology Group; VGPR, very good
partial response; SD, stable disease.
Data presented are n (%) unless otherwise indicated.
* One case was reported as biclonal gammopathy, which is primarily IgA-
kappa with a smaller IgG-kappa band.
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The primary endpoint was to evaluate the 6-month response by
International Myeloma Working Group uniform response criteria [32].
The secondary efﬁcacy endpoints included overall survival (OS) and
progression-free survival (PFS). These endpoints were analyzed as time-to-
event variables, which were deﬁned as the time from transplantation to
death for OS and the time from transplantation to disease progression or
death, whichever occurred ﬁrst, for PFS. The event-free probabilities for
these endpoints were estimated using the Kaplan-Meier method. Patients
without events were censored at the last follow-up for OS and at the last
disease evaluation for PFS. Safety evaluation included TRM, which was
deﬁned as death after transplantation due to any cause other than disease
progression and as SOS as deﬁned by the Baltimore criteria [33].RESULTS
Patient Demographics
Thirty patients were enrolled at 11 institutions from the
United States and Canada between June 2010 and July 2011.All enrolled patients completed the protocol regimen and
received a second salvage autotransplantation. Of the pa-
tients, 83.3% were male and 86.7% were Caucasian (Table 1).
Median time from initial diagnosis to second autologous
transplantation was 38.5 months (range, 19 to 125). Median
time from ﬁrst to second transplantation was 28.0 months
(range, 12 to 119). Median age at second transplantation was
59 years (range, 48 to 73). Extramedullary disease was pre-
sent in 4 patients (13.3%) at study screening.
At initial diagnosis, 17 patients (56.7%) had normal cyto-
genetics, 11 patients (36.7%) had cytogenetic abnormalities,
and 1 patient had no evaluable metaphases (3.3%). Cytoge-
netic abnormalities were reported in 6 patients (20.0%) at
study screening. Cytogenetic 13q deletion was recorded in 3
patients at initial diagnosis and in 1 patient at second
transplantation.
Before the second transplantation, all patients were
treated with at least 1 of 3 drugsdbortezomib, thalidomide,
or lenalidomidedand 13 patients (43.3%) received radio-
therapy for myeloma. Twenty-six patients (86.7%) received
prior therapy with bortezomib and 23 patients (77.0%)
received prior therapy with thalidomide and/or lenalido-
mide. Single-agent melphalan was used as the conditioning
regimen for the ﬁrst autotransplantation in all patients. One
patient had a tandem transplantation before enrolling in the
study; this patient was excluded from the survival analysis.
The salvage or reinduction therapy for relapsed myeloma
before the second autotransplantation is illustrated in
Table 1. Twenty patients (66.7%) had residual sensory neu-
ropathy without pain (18 with grade 1 and 2 with grade 2) at
enrollment. Eastern Cooperative Oncology Group perfor-
mance status was grade 0 in 11 patients (36.6%), grade 1 in 18
patients (60.0%), and grade 2 in 1 patient (3.3%).
At second transplantation, seven patients (23.3%) had a
very good partial response, 12 patients (40.0%) had a partial
response (PR), 2 patients (6.7%) had stable disease, and 9
patients (30.0%) had progressive disease (PD).
Seizure Prophylaxis
No speciﬁc drug or drug combination for seizure pro-
phylaxis was required in the study. Twenty-one patients
used lorazepam, 9 patients used levetiracetam, and 6 pa-
tients used both drugs.
Selection of Bu Exposure
No CLT was reported from the ﬁrst 2 cohorts of 3 patients
each, whose i.v. Bu was targeted to 20,000 mM minute as a
total AUC. Therefore, de-escalation of Bu was not necessary.
After the data safety monitoring board reviewed safety data
and veriﬁed that 20,000 mM minute was a tolerable target
total AUC, 24 additional patients were enrolled using this
target AUC.
Test Dose and Conﬁrmatory PK (Supplemental Table 1)
Mean Bu clearance (CL) for the Bu test dose of .8 mg/kg
was 3.03 mL/minute/kg. After the test dose, 40% of patients
had an AUC outside of the expected range (<1000 or
>1500 mM  minute) (Figure 3A). No clinical or laboratory
parameter was capable of identifying patients whose AUC
fell outside the target range. Based on this PK analysis, the
dose of Bu for the conditioning regimen was determined for
each patient.
Conﬁrmatory PK results on day 5 of the conditioning
regimen revealed that mean Bu CL was 2.93 mL/minute/kg,
which was similar to the CL of the test dose. Accordingly,
Figure 3. (A) Preconditioning test pharmacokinetics (PK) results. After a test i.v. Bu dose of .8 mg/kg, 40% of patients had an area under the curve (AUC) outside of the
expected range: n ¼ 11 (<1000 mM  minute) or n ¼ 1 (>1500 mM  minute). (B) Total estimated AUC from preconditioning test PK and 4-day conditioning.
Histograms indicate total Bu AUC exposure from a test dose (.8 mg/kg) and from 4-day administration during the conditioning regimen using individualized doses of
i.v. Bu. The total estimated AUC exposure over 5 days fell within the target range (AUC, 20,000 mM  minute  20%).
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tive days. Two patients (6.7%) needed downward dose
adjustment during the conditioning regimen because of
decreased Bu clearance from test PK to conﬁrmatory PK.
These 2 patients would have had out-of-target AUC for the
last 2 doses of Bu if conﬁrmatory PK had not been carried
out. Consequently, the total estimated AUC exposureover 5 days fell within the target range (AUC,
20,000 mM  minute  20%) in all patients (Figure 3B). The
total mean dose of i.v. Bu (including the test dose and
4-day administration) was 14.2 mg/kg (standard
deviation ¼ 2.48; range, 8.7 to 19.2). This is approximately
11% more than 12.8 mg/kg, the dose recommended based
on body weight.
Table 2
Incidence of Treatment-Related Adverse Events with Toxicity Grade Three
Occurring in at least Two Subjects
Adverse Event Grade
Three n (%)
Grade
Four n (%)
Total Events
of All Grades
n (%)
Febrile neutropenia 14 (46.7) 1 (3.3) 17 (56.7)
Stomatitis 12 (40.0) 1 (3.3) 28 (93.3)
Nausea 3 (10.0) 1 (3.3) 24 (80.0)
Fatigue 2 (6.7) 0 (0.0) 20 (66.7)
Hypokalemia 3 (10.0) 0 (0.0) 15 (50.0)
Hypotension 1 (3.3) 1 (3.3) 7 (23.3)
Hypophosphatemia 2 (6.7) 0 (0.0) 6 (20.0)
Pain in extremity 2 (6.7) 0 (0.0) 6 (20.0)
Hypoxia 1 (3.3) 1 (3.3)* 4 (13.3)
Hallucination 2 (6.7) 0 (0.0) 4 (13.3)
Renal failure acute 1 (3.3) 1 (3.3) 3 (10.0)
Sepsis 1 (3.3) 1 (3.3) 2 (6.7)
* Treatment-related death.
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Twenty-nine patients received blood progenitor cells
and 1 patient received bone marrow. Twenty-eight pa-
tients underwent transplantation with progenitor cells that
were harvested before the ﬁrst transplantation, 1 subject
used progenitor cells harvested before the second trans-
plantation, and 1 subject used both. The median number of
infused CD34þ cells was 3.8  106/kg (range, 2.1 to 13.8).
Post-transplantation granulocyte-colony stimulating factor
was used in 27 patients (90.0%). Median times to neutro-
phil count >500/mL and platelet count >20,000/mL were
11 days. Median time to platelet count >50,000/mL was
14 days.Table 3
Disease Response in Individual Subjects after Second Autologous Transplantation
Response
at Study Entry
Response at
Three Months
Response at
Six Months
R
E
VGPR SD Allo after 3 months S
VGPR VGPR* sCR*
VGPR SD SD*
VGPR Transplantation-related death on day 5
VGPR CR CR*
VGPR VGPR VGPR
VGPR SD PD
PR PD P
PR PR SD
PR SD SD
PR VGPR VGPR
PR PR PD*
PR PD P
PR VGPR VGPR
PR PD P
PR SD* LFU
PR PR PD P
PR Lost follow-up before 3 months
PR SD PD
SD PD P
SD PD P
PD PD P
PD PD P
PD PD P
PD PD
PD VGPR PD P
PD SD SD
PD CR VGPR*
PD SD SD
PD PR SD
ASCT indicates autologous stem cell transplantation; Allo, allogeneic transplantation
* Response assessment after administering maintenance therapy.Toxicity
Incidence of all observed AEs with extramedullary
toxicity grade  3 occurring in at least 2 cases are listed in
Table 2. One treatment-related death occurred on day 5 after
transplantation in a 54-year-old male patient with multiple
comorbidities, who died of pneumonitis. Normal Bu
exposure was observed in this case as the total estimated
AUC was 17,798 mMminute from the total administered Bu
dose of 14.6mg/kg (.8mg/kg for test PK plus 3.4mg/kg/day
4 days).
The most frequently observed grade 3 or 4 AEs were
febrile neutropenia in 15 patients (50.0%), stomatitis in 13
patients (43.3%), and nausea in 4 patients (13.3%). There was
no clear correlation between Bu exposure and the incidence
and severity of stomatitis (data not shown). No cases of SOS
were diagnosed as deﬁned by the Baltimore criteria.
No new cases of sensory neuropathy were observed. Of 20
patients who had sensory neuropathy at baseline, only 1
patient experiencedworsening of the neuropathy from grade
1 to 2. The neuropathy improved in 8 patients and no change
in neuropathy was reported in 10 patients. One case was not
evaluable because of early death. No instances of seizure
were reported, as all patients took lorazepam and/or leve-
tiracetam as seizure prophylaxis from the night before
starting Bu until 1 day after the last dose of Bu.
Three consecutive ECGs on day 1 showed no signiﬁcant
QTc prolongation compared with the ECG at study entry.Disease Response
One patient died of transplantation-related complications
and another patient withdrew consent less than 3 monthsesponse at
arly Termination
Best Response
after Second ASCT
Months from First
to Second ASCT
D SD 20
NE 21
SD 25
26
CR 39
VGPR 49
SD 59
D PD 18
PR 19
SD 21
VGPR 21
PR 22
D PD 24
VGPR 27
D PD 41
e 48
D PR 49
70
SD 73
D PD 32
D PD 38
D PD 12
D PD 15
D PD 18
PD 21
D VGPR 38
SD 29
CR 45
SD 48
PR 119
; NE, not evaluable; sCR, stringent complete response; LFU, lost to follow-up.
Table 4
Retrospective Studies for Second ASCT to Salvage Relapsed Myeloma
Study Group Princess
Margaret Hospital
University of
Pennsylvania
University of
Texas, San Antonio
San Bortolo
Hospital, Italy
BSBMT
Registry
CIBMTR
Registry
No. subjects 81 41 25 26 148 187
Age, median (range), yr 55 (30-67) 54 (28-73) 58 (39-73) NA 53 (26-75) 59 (28-74)
Interval between ﬁrst
and second ASCT,
median (range), mo
39 (median time
to relapse
after the ﬁrst
transplantation)
37 (3-91) 39 (4-74) 20.4 (3-91) NA 32 (6-122)
Regimen for second HSCT MEL (n ¼ 78)
MEL/TBI/etoposide
(n ¼ 1)
Others (n ¼ 2)
MEL (n ¼ 23)
MEL/TBI (n ¼ 14)
BU/CY(n ¼ 3)
CY/TBI (n ¼ 1)
MEL (n ¼ 25) Oral Bu 12 mg/kg þ
MEL 120 mg/m2
Multiple
TBI ¼ 11
No TBI ¼ 133
MEL (n ¼ 158)
Others (n ¼ 29)
Response at Second ASCT CR 0%
VGPR 12.5%
PR 73.8%
Less than PR 13.8%
NA
(37% had responsive
disease at
second ASCT)
CR 0%
PR 24%
MR/NR 28%
PD 48%
NA NA CR/PR 40%
MR/NR/SD 46%
Relapse/PD 14%
Response after second ASCT CR 7.7%
VGPR 39.7%
PR 50%
SD 1.3%
PD 1.3%
CR 5%
VGPR 10%
PR 37%
SD 27%
PD 15%
CR 20%
PR 44%
MR/NR 12%
PD 8%
CR 3.8%
VGPR 11.5%
PR 53.8%
MR 19.2%
SD/PD 11.5%
CR 26%
PR 37%
CR 25%
PR 43%
MR 6%
SD 16%
PD 10%
PFS, median, mo 16.4 8.5 12 14.8 32% at 4 yrs 11.2
OS, median, mo 53 20.7 19 38.1 NA 30
TRM 2.6% (all death) 7% (at day 100) 8% 0% 8% (at day 100) 2% (at Year 1)
Reference [2] [3] [1] [4] [5] [6]
BSBMT indicates British Society for Blood and Marrow Transplantation; CIBMTR, Center for International Blood and Marrow Transplant Research; NA, not
available; HSCT, hematopoietic stem cell transplantation; MEL, melphalan; TBI, total body irradiation; Cy, cyclophosphamide; MR, minimal response; NR, no
response.
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(Table 3). Assessment of response excluded response after
initiating maintenance therapy because it did not necessarily
reﬂect the efﬁcacy of the conditioning regimen. At 3 months
after transplantation, 10 of 26 patients attained a PR or better
response, including 2 patients who attained a complete
response (CR). Of 9 patients who had PD at second trans-
plantation, 3 experienced at least a PR at 3 months after
transplantation, including 1 CR and 1 very good PR. At
3 months after transplantation, 9 patients had experienced
PD, 2 of whom died.
Seventeen patients remained on the study 6 months after
transplantation, 5 of whom received maintenance chemo-
therapy. Of the remaining 12 patients, 5 patients maintained
their response and 7 patients experienced PD.
Maintenance therapy was initiated in 2 patients within
3 months after transplantation: 1 patient attained stringent
CR at month 6 after transplantation and the other 1 was lost
to follow-up.
Four patients startedmaintenance therapy between 3 and
6 months after transplantation. Two patients did not expe-
rience any change in the status of their disease and 2 patients
experienced PD.
PFS and OS
Median PFS was 191 days, whereas median OS was not
reached during the study period. The interval duration be-
tween transplantations did not correlate with PFS. Specif-
ically, the median PFS was 183 days for patients with an
interval  24 months (n ¼ 18) compared with 191 days for
patients with an interval of< 24months (n¼ 11). Those with
 10% of plasma cell percentage in bone marrow at second
transplantation (n ¼ 10) had a median PFS of 92 days,
whereas the median PFS was not reached in those with a
plasma cell percentage in bone marrow <10% (n ¼ 17).
Because of the small number of the sample, statistical anal-
ysis is not reported.DISCUSSION
The purpose of this study was to determine the safety and
efﬁcacy of a novel combination of i.v. Bu and bortezomib for
patients undergoing a second autologous transplantation for
MM. As the i.v. Bu exposure was untested in patients
receiving this combination, Bu was initially targeted to
20,000 mM  minute AUC, an exposure used frequently in
hematologic malignancies. We demonstrated that this Bu
exposure was safe after no CLTs were observed during the
initial part of this study.
The toxicity of this regimen was acceptable. Only 1 pa-
tient died of a treatment-related pulmonary complication.
The most common severe toxicities were febrile neutropenia
and stomatitis, which occurred in 50% and 40% of patients,
respectively. These toxicities are frequently experienced after
high-dose chemotherapy but the frequency of stomatitis was
higher in our study compared with that reported after high-
dose melphalan [1]. In our study, 93% of patients developed
mucositis, 40% of them grade 3. Of 20 patients who had
sensory neuropathy at study entry, only 1 patient experi-
enced worsening of the neuropathy from grade 1 to 2.
Neuropathy improved in 8 patients despite the use of bor-
tezomib as part of the conditioning regimen. Of importance
is the fact that no patient developed SOS, a toxicity that has
limited the use of oral Bu in conditioning regimens for he-
matologic malignancies.
This study demonstrated that the combination of i.v. Bu
and bortezomib is active in myeloma, even in relapse after a
preceding transplantation. Despite the fact that most pa-
tients had received bortezomib and immunomodulatory
drugs and one third of patients had PD at the time of the
transplantation, more than one third of evaluable patients
had at least a PR 3 months after the second transplantation.
The true response rate to this regimen is probably under-
stated, as in this study any disease response after initiating
maintenance therapy was excluded from the response
analysis. At 6 months after transplantation, 5 of 12 evaluable
C.O. Freytes et al. / Biol Blood Marrow Transplant 20 (2014) 1949e19571956patients hadmaintained or improved their response. Median
PFS in this study was 191 days, whereas median OS was not
reached during the study period.
The role of maintenance therapy after a salvage auto-
transplantation is unknown. For this reason, it is hard to
ascertain the inﬂuence of maintenance therapy in the
outcome of patients in this study. Of 2 patients who started
maintenance therapy before the 3-month evaluation, 1
attained stringent CR at 6 months after transplantation and
the other was lost to follow-up. Of 4 patients who started
maintenance therapy between 3 and 6 months after trans-
plantation, 2 remained with stable disease and the other 2
experienced PD.
In this study, PK analysis after a test dose of i.v. Bu allowed
for optimization of the i.v. Bu dose utilized in the condi-
tioning regimen. After the test dose of i.v. Bu, 40% of patients
had an AUC outside of the expected range. The total AUC
from these patients during the conditioning regimen would
have fallen outside the target total AUC (<16,000 or
>24,000 mM minute) if a ﬁxed dose of i.v. Bu based on the
patient’s weight had been used. Conﬁrmatory Bu PK analysis
performed during the ﬁrst day of the conditioning regimen
demonstrated that only 2 of 30 patients needed dose
adjustment of i.v. Bu during the last 2 days of the condi-
tioning regimen to attain the target AUC. Despite the large
numbers of samples required for PK analysis and the fact that
a central reference laboratory was used, our multicenter
study demonstrates that this approach is feasible and could
be implemented widely.
When compared with other reports of salvage auto-
transplantation for patients with MM, our patients had a
much shorter time interval between transplantations
(28 months) compared with most studies, in which the time
intervals were 32 to 39 months, suggesting that our patients
had more aggressive disease (Table 4) [1,3,6]. Only 1 study
from San Bartolo Hospital had a shorter interval between
transplantations than our study [4]. Another indication that
our study population had very aggressive diseasewas that, at
the time of enrollment, there were no patients in complete
remission andmore than one third of the patients had PD. On
the other hand, we excluded patients with adverse cytoge-
netic features whereas other studies did not. Despite these
adverse clinical factors, 38% of evaluable patients attained a
partial remission or better response after the second trans-
plantation, including 2 patients who attained CR.
In summary, this study demonstrated that a Bu AUC of
20,000 mM minute is safe in patients with MM undergoing
autotransplantation with Bu and bortezomib. This novel
combination induced a PR or better in one third of heavily
pretreated patients who failed a previous auto-
transplantation with acceptable toxicity. Further studies are
warranted to evaluate the combination of PK dose-targeted
i.v. Bu with other active agents in patients with MM. These
studies should include patients with more favorable char-
acteristics and explore using higher doses of bortezomib or
other chemotherapeutic agents. The use of a uniform post-
transplantation therapy should facilitate the assessment of
novel regimens.
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